The MONALEESA-3 study in HR+/HER2- advanced breast cancer

Neelima Denduluri, MD, discusses the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in HR+/HER2- advanced breast cancer